Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Center for Drug Evaluation, the most common co-covered peer. They are better corroborated than the beat average, carrying 10 original sources each against 3.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Hope Medicine Inc.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Center for Drug Evaluation, the most common co-covered peer. They are better corroborated than the beat average, carrying 10 original sources each against 3.3 for the same window. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. We currently track 1 Healthcare story that mention Hope Medicine Inc., all published on March 25, 2026.
Stories tracked
1
Sources per story
10
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Hope Medicine Inc.. Shared-story counts are live from our verified record — not editorial picks.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.